St Jude Medical Inc
Latest St Jude Medical Inc News and Updates
Company & Industry Overviews A Brief Recap of the Abbott–Alere Deal Developments
Three months after announcing a $5.8 billion deal in which Abbott Laboratories (ABT) would buy Alere (ALR), Alere rejected Abbott’s $50 million offer to end the deal. On December 7, Abbott sued Alere to terminate the deal.Company & Industry Overviews Atrial Fibrillation Ablation Could Be a Short-Term Growth Driver for MDT
More than 33 million patients suffer from AF, the most common form of heart arrhythmia. About 30% of these patients respond to antiarrhythmic drugs (or AAD).Company & Industry Overviews Medtronic Expands Capabilities of Implantable Cardioverter Defibrillators
On May 2, 2016, the FDA approved Medtronic’s (MDT) Visia AF and Visia AF MRI Surescan. These devices are single-chamber implantable cardioverter defibrillators (or ICDs) capable of detecting asymptomatic and undiagnosed atrial fibrillation.Company & Industry Overviews Inside Edwards Lifesciences’ THV Product Pipeline and Future Growth Estimates
Edwards Lifesciences (EW) has a robust product pipeline in its THV (transcatheter heart valve) segment, with Sapien 3 as the segment’s leading product.Company & Industry Overviews The Rationale behind Johnson & Johnson’s Acquisition of Abbott Medical Optics
On September 16, 2016, Johnson & Johnson announced the acquisition of Abbott Medical Optics, a subsidiary of Abbott Laboratories, and its stock fell ~0.3%.Company & Industry Overviews The Business Strategies Driving Boston Scientific’s Growth
Boston Scientific registered emerging market sales growth of approximately 13% in 2015, representing a steady growth in international markets.Company & Industry Overviews Understanding Boston Scientific’s MedSurg Segment
Boston Scientific’s (BSX) MedSurg segment contributes around 33% to the company’s total revenues and is the company’s second-largest segment.Company & Industry Overviews A Brief Look at Boston Scientific’s Business Model
Boston Scientific’s (BSX) Cardiovascular segment consists of minimally invasive technologies to treat patients with a wide range of heart and vascular diseases. It is BSX’s largest business segment and generated ~39% of the company’s total revenues in 2015.Miscellaneous Rationale for the St. Jude Medical-Abbott Merger Transaction
Abbott Labs is buying St. Jude Medical for about $30 billion in cash, stock, and assumed debt to become a dominant player in the cardiovascular health space.Miscellaneous Abbott Buys St. Jude Medical for $85 per Share in Cash and Stock
On April 28, Abbott Labs and St. Jude Medical announced an agreement where Abbott will buy St. Jude for $30 billion in cash, stock, and assumed debt.Company & Industry Overviews Probing Medtronic’s Research and Development Pipeline
Medtronic spent ~$1.6 billion—approximately 8.1% of its total sales—on research and development programs in fiscal 2015.Company & Industry Overviews A Key Breakdown of Medtronic’s Business Model
Medtronic generates revenue through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies, Restorative Therapies, and the Diabetes Group.